What does the German Act on the Reform of the Market for Medicinal Products mean for Psychopharmacotherapy?

In the April issue of the German journal “Nervenarzt” I published an article entitled “Significance of the German Act on the Reform of the Market for Medicinal Products for psychopharmacotherapy” (Nervenarzt 2016; 87: 356-366). This law, abbreviated as AMNOG, which took effect in Germany on January 1st, 2011, had already significant effects on the availability of psychotropic drugs in Germany. The full consequences of the policy are not yet fully foreseeable, but they might in the long term be even positive not only for psychopharmacology, but for the entire field of psychiatry. The article, which is only available in German language, can be downloaded as a PDF here.

Why do I post so few articles here at the moment? I’m working on a brand new website, which will provide a much broader perspective on our profession –  and not only on psychiatry. This will take some time, and until the launch of the new website there will be unfortunately only sparse new posts. I appreciate your understanding!